Normal Molecular Weight of Type VII Collagen Produced by Recessive Dystrophic Epidermolysis Bullosa Keratinocytes  by Jenison, Mark et al.
Normal Molecular Weight of Type VII Collagen 
Produced by Recessive Dystrophic Epidermolysis 
Bullosa Keratinocytes 
Mark Jenison, J 0-David Fine, W . Ray Gammon, and Edward J. 0 'Keefe 
Department of Dermatology, University of North Carolina, Chapel Hill, North Carolina, U .S.A. 
Studies of the recessive dystrophic form of epidermolysis 
bullosa (ROEB) have suggested that an abnormality in type 
VII collagen may be involved in the pathogenesis of this 
disorder. Indirect immunofluorescence studies have shown 
that .the staining for type VII collagen along th~ dermal-epi-
dermal junction is markedly reduced or absent 1Il all but rare 
cases of severe, generalized ROEB. These findings imply that 
the genetic defect may involve type VII collagen but do not 
exclude the possibility that the alterations demonstrated are 
secondary, for example, to nonspecific proteolysis of type VII 
collagen. To evaluate the ability of cells of affected patients to 
produce type VII collagen, we cultured keratinocytes from a 
Pearson was the first to note that patients with severe, generalized forms of recessive dystrophic epidermolysis bullosa (RDEB) have an abnormal ultrastructure at the dermal-epidermal junction [1]. It was later confirmed that these distinctive fibrillar structures, named anchor-
ing fibrils [2], were either absent or markedly reduced in number in 
patients with RDEB [3]. Other studies have subsequently con-
firmed these findings [4,5] . Type VII collagen was later found to be 
the major component of the anchoring fibril [6 - 8], and immunoflu-
orescence studies using antibodies directed against type VII collagen 
have confirmed that type VII collagen appears to be reduced or 
absent within unblistered skin from patients with severe generalized 
RDEB [9-14]' 
Although type VII collagen has been implicated by inference in 
such studies as the possible etiologic defect in severe, generalized 
RDEB, the mechanism of the abnormality has not as yet been fully 
investigated. For example, it is not known whether patients with 
severe generalized RDEB express normal or reduced amounts of a 
mutant form of type VII collagen or have reduced amounts of a 
structurally normal type VII collagen, or, alternatively, whether the 
observed reduction in type VII collagen is a reflection of enhanced 
proteolysis secondary either to a structurally altered form of type 
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severely affected patient and immunoprecipitated type VII 
collagen from the cells. Keratinocytes were metabolically 
labelled with 35S-methionine, and solubilized cell extracts 
were reacted with antibody to type VII collagen. The results 
indicate that the patient's keratinocytes synthesize type VII 
collagen and that the M. of the protein synthesized does not 
differ from that of an unaffected control. Because cultured 
cells from a patient severely affected with recessive dystro-
phic :pidermolysis b~llosa. pro~uce type VII collagen, the 
genetic defect, at least 1Il thIS patient, is unlikely to reside in a 
major truncation of the type VII collagen molecule. ] Il1vest 
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VII c?llagen or to ex:cessive amounts of collagenase [15 - 17]. To 
examl1le the productiOn of type VII collagen in RDEB, we have 
examined the protein produced by keratinocytes by metabolic label-
ing and immunoprecipitation. Our studies indicate that the protein 
is produced and appears to be normal in some respects. 
MATERIALS AND METHODS 
~tibodies We used the ammonium sulfate-precipitated frac-
tIon (IgG = 1.24 mgjrnl) from the serum of a patient with epider-
molysis bullosa acquisita to immu~opr~cipita~e type VII collagen 
from extracts of cultured cells. ThiS antibody IS known to identify 
the noncollagenous domai.n of o/pe VII cO.llagen [18] and was a gift 
of Dr. D. Woodley. Rabbit antl-fibronectln has been characterized 
previously [19]. 
C~ll Culture and Meta~olic Labeling Keratinocytes were ob-
tained from the truncal skin of a severely affected adult patient with 
the Hallopeau-Siemens form of generalized RDEB (gravis form) 
[20] and, as a control, from a normal adult. The patient with RDEB 
~nd. he~ two affected brothers . w~r~ treated for many years at this 
inStitutIOn. All ~hree affected Indjvlduals had experienced marked 
growth retardation, severe anemIa, esophageal strictures, mutilat-
ing mitten-like deformities of the hands and feet, severe intraoral 
disease activity with scarring, and recurrent squamous cell carcino-
mas of the skin. In the case of our patient, squamous cell carcinoma 
metastasized and was directly responsible for her death. Indirect 
immunofluorescence on this patient's skin using monoclonal anti-
body LH 7: 2 [9] to type VII collagen at 1: 40 dilution which 
readily d~~onstrates the protein in normal skin, failed to demon-
strate stalnll1g for type VII collagen at the dermal-epidermal junc-
tion (not shown). 
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Keratinocytes were obtained and initiated into culture according 
to the method of Rheinwald and Green [21]. Both normal and 
RDEB keratinocytes were then subcu ltured in MCDB 153 medium 
with appropriate supplements (using a modification [22] of the 
method of Boyce and Ham [23]) and passaged six times (normal 
keratinocytes) or seven times (RDEB keratinocytes) to remove a~y 
contaminating fibrobl asts. Cells were grown to near confluence 111 
35-mm petri dishes, washed three times with Hoan~s' balan.ce~ sa-
line solution (HBSS), and 1I1cubated for 1 hat 37 C 111 methlomne-
free MCDB 153 with all other appropriate supplements. The media 
in all petri dishes were then replaced with methionine-free MCDB 
153 containing 50 /1-Ci )SS-methionine (Trans-label 51006; lCN, 
Irvine, CAl per ml and incubated at 3rc for 18 h. 
All subsequent steps were carried out at 4 ° C . After the medium 
was decanted from each petri dish, the cell layers were washed three 
times with HBSS containing 0.1 mM Ca++ and then incubated for 
2 min in 1 ml of 0.1 M Tris-HCl, pH 6.8, containing 0.5% Noni-
det P-40, 0.5% sodium deoxycholate, 0.1 % SDS, 1 mM ethylene-
diamine tetraacetate, and 2 mM phenylmethylsulfonyl fluoride 
(RlPA buffer) . The cells and buffer were then scraped off the dish, 
vortexed for 1 min, sonicated for 30 sec, and centrifuged at 
100,000 X g for 30 min. The extracts were diluted in RlPA buffer 
to 2-8 X 106 cpm/ml. 
Immunoprecipitation Procedures Immunoprecipitation of 
type VII collagen was carried out. essentially according to proce-
dures described previously [24] usmg the extracts prepared as de-
scribed above. Samples were pre-incubated with antifibronectin an-
tibody to remove fibronectin, because without this procedure 
radiolabeled fibronectin in the samples bound nonspecifically to 
protein A-Sepharo~e and obscured t~e type VI! collage.n band. 
Protein A-beating staphylococCl (Pansorbm; Calblochem, La 
Jolla, CAl were washed in 9 vol of 10 mM sodium phosphate 
buffer, pH 7.4, containing 1% SDS and 0.15 M NaCi; heated to 
60°C for 15 min; centrifuged at 2000 Xg for 15 min; diluted in 
10 mM glycine containing 2 M urea and 1 % Triton X-lOO; washed 
three times by centrifugation in 10 mM sodium phosphate buffer 
containing 0.1 M NaCl, 1 mM EDTA, 0.1% Triton X-I00, and 
1 mM NaN); and stored at 10% (v /v) in this buffer. 
Each I-ml sample of cell extract described above was pre-ab-
sorbed for 3 h at 4 ° C on a rotating wheel with 10 ttl normal human 
serum, 10/1-1 rabbit anti-human fibronectin serum, and 122/1-1 lOX 
extraction buffer (6% Nonidet P-40, 3% sodium deoxycholate, 
2 .35 M NaCl, 1 % bovine serum albumin, 0.02% sodium azide in 
tris-buffered saline (TBS) [0 .01 M Tris-HCI, pH 7.4, 0.15 M 
NaCl]) in a 1.5-ml Eppendorf tube. The samples were then trans-
ferred to fresh 1.5-ml Eppendorf tubes containing the extensively 
washed pellet from 0.5 ml of 10% Pansorbin, incubated for 90 min 
on a rotating wheel at 4°C, and centrifuged in a Beckman Micro-
fuge 12 at full speed for 5 min. The supernatant was divided into 
two 0.5-ml aliquots and transferred to fresh 1.5-ml Eppendorf tubes 
containing 40/1-1 anti-type VII collagen antibody or 10/1-1 control 
serum, incubated at 4 °C for 16 h, and centrifuged for 5 min at full 
speed in a Beckman Microfuge. The supernatant was transferred to a 
fresh tube containing 100/1-1 Sepharose CL-4B coupled to protem A 
(Sigma Chemical Corp., St. Louis, MO) and incubated for 30 min at 
room temperature and then for 1 h at 4°C on a rotating wheel. 
Samples were washed three times with 1 ml washing buffer (0.3% 
Nonidet P-40, 0.3% sodium deoxycholate, 0.5 M NaCI, 0.02% 
NaN), 0.01 M Tris-HC1, pH 7.4) containing 0.1% bovine seruhl 
albumin, three times with 1 ml washing buffer, and once with 
distilled water. Samples were then transferred to fresh tubes and 
aspirated to dryness with a 27-gauge needle. The Sepharose beads 
were suspended in 2X Laemmli sample buffer [25], heated to 75 ° C 
for 3 min, and centrifuged briefly in a Beckman Microfuge. Equal 
volumes of the supernatants were analyzed by SDS polyacrylanlide 
gel electrophoresis on 5% ~olyacrylamide gels [25]' T~e gels were 
dried and fluorographed With Kodak X-Omat film US1l1g Fluoro-
hance autoradiography enhancer (RPI Corp., Mt. Prospect, IL) ac-
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Figure 1. Molecular weight of type VII collagen from ROEB and normal 
keratinocytes. Keratinocytes were metabolically labeled and type VB col-
lagen was immunoprecipitated, as in Materials alld Methods. Lalles 1-4, 
normal keratinocyte control; latles 5 -8, ROEB keratinocytes. Antibody to 
type VII collagen was used in lalles 2,4,5, 7; control serum was used in lanll 
1,3, 6,8. The two rmmarked laolcs at the left show labeled extracts from 
normal keratinocytes before immunoprecipitation. Molecular weight 
standards are shown at left. 
cording to the manufacturer's instructions. Contact prints were 
made from the auto radiograms. 
RESULTS 
Figure 1 shows a 290-kDa band representing the major protein 
immunoprecipitated from extracts oP5S-labeled normal cel ls in our 
experiments (lanes 2,4). This band was not present in lanes in which 
control serum had been used (lanes 1,3) and was therefore specifi-
cally immunoprecipited by the antiserum to type VII collagen. 
These results are comparable to previous work using this antiserulU 
[18,26] and indicate that type VII collagen was immunoprecipitated 
under the conditions of our experiments. 
Figure 1 also shows the immunoprecipitate of metabolically la-
beled type VII collagen from a patient with RDEB (lall es 5 and 7). As 
in the case of the normal cells, control antiserum did not appear to 
precipitate any proteins (latles 6 a~ld 8). The bands of. type VII colla· 
gen from a severely affected patient With RDEB did not differ tJ1 
mobility from the control. In this experiment, therefore, type V1l 
collagen from RDEB keratinocytes cannot be distinguished frorn 
that from normal cells by its mobility on SDS gels. This suggests 
that if type VII collagen is abnormal in these conditions it is not 
sub~tantially altered wit!: respect to the length of the poiypeptide 
cl~alll. The results establtshed clearly that in at least one pedigree 
~Ith severe, generaltzed RDEB, type VII collagen is produced ill 
vitro. The gene for type VII collagen is therefore present and tran-
scribed, and mRNA is translated . 
T~le.re is a reduction in the amount of type VII collagen immuno-
p.rec~pltated from the affected cells in our experiments, but the 
slg~lficance ?f tillS result cannot be established based upon our ex-
penments With the cell s of a single RDEB patient. Such a result may 
depend on growth characteristics of the cells in culture or other 
factors; the determination of whether a reduction in the quantity of 
type VII collagen produced by RDEB cells is significant in our 
experiments will require comparison with results using cells from a 
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large number of other RDEB patients. It is interesting to note that 
there was no apparent proteolysis of the 290-kDa band by the 
ROEB cells with the production of lower molecular weight frag-
ments in our experiments. The finding of others of two bands iden-
tified by antibody to type VII collagen on immunoblots from skin of 
a patient with RDEB inversa (27] is suggestive of proteolysis, which 
could be a feature of the disease or secondary to it. It will be of 
interest to determine whether metabolically labeled type VII colla-
gen from other RDEB patients or from patients with the inversa and 
centripetalis forms ofRDEB who also appear to have alterations in 
type VII collagen [14,28,29] differs from that of our patient. 
Our results do not exclude the possibility that type VII collagen is 
involved in the pathogenesis of RDEB. First, deletion of even a 
substantial number of amino acids might not be apparent in our 
studies. Second, the type VII collagen produced could be normal in 
size but functionally abnormal. Because collagen must bind to other 
matrix proteins, its binding functions may be significantly altered. 
post-translational modifications of the polypeptide could also be 
defective. Such modifications, either in primary structure or in gly-
cosylation or phosphorylation, for example, might also render it 
unusually susceptible to proteolysis. Susceptibility to proteolysis 
may indeed explain the moderate to drastic reductions in type VII 
collagen described in immunofluorescence studies. Third, a reduc-
tion in the quantity of type VII collagen produced may reduce the 
functional integrity of the anchoring fibrils. Finally, evidence is 
strong that inheritance of a related disorder, dominant dystrophic 
epidermolysis bullosa, is closely linked to the gene for type VII 
collagen [30] . 
DISCUSSION 
Because our study used keratinocytes, it was of interest to address 
the question of the origin of type VII collagen in the skin . Both 
keratinocytes and dermal fibroblasts can synthesize type VII colla-
gen [31- 3.3]: Briggan:an and Wheeler [3] s~owed that recombinant 
skin contalnlllg dermiS from an RDEB patient and normal epider-
mis reproduced the phenotype, abnormal anchoring fibrils, when 
cultured on a chick chorioallantoic membrane, whereas normal 
dermis combined with RDEB epidermis did not; they suggested 
that the abnormality in anchoring fibrils depends in some way on 
the dermis. Recent work, however, provides evidence that the spe-
cific collagen molecules making up anchoring fibrils may be derived 
from the epidermis [34,35]. Although the question may not be 
resolved at present, it is possible, if not likely, that type VII collagen 
in the cutaneous basement membrane, like fibronectill [36]. origi-
nates in the epidermis. Because antibodies to type VII collagen 
identify the protein from both keratinocytes and dermal fibroblasts 
[31 - 33], it is possible that both molecules represent the same gene 
product. 
Additional studies will be required to determine whether abnor-
malities in the primary structure or post-translational modifications 
are present in RDEB type VII collagen. Recent cDNA cloning of 
type VII collagen [37] will facilitate the determination of its primary 
structure in RDEB. Our experiments suggest that a major trunca-
tion of the protein or severe reduction in synthesis is not likely to be 
responsible for the demonstrated abnormalities in the skin and, if 
defective type VII collagen underlies RDEB, that small deletions or, 
more likely, point mutations may be demonstrated. The possibility 
that the protein is rapidly degraded in vivo cannot be ruled out, but 
this was not apparent in vitro. Additional studies will be required to 
determine w hether minor modifications in the RDEB type vn 
collagen might be demonstrated by measurements of isoelectric 
points or susceptibility to proteolytic cleavage and to determine 
whether heterogeneity of type VII collagen expression is demonstra-
ble by immunoprecipitation using cells from additional patients. 
These results do demonstrate definitively, however, that the produc-
tion of type VII collagen by keratinocytes is compatible with the 
RDEB phenotype. 
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